IN BRIEF: Hutchmed highlights positive lung cancer test results

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 ...

Alliance News 20 March, 2025 | 2:31PM
Email Form Facebook Twitter LinkedIn RSS

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC.

Current stock price: 252.00 pence each, up 2.9% Thursday afternoon in London

12-month change: down 7.0%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 11,416.00 GBX 1.96
HUTCHMED (China) Ltd 237.00 GBX 0.85 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures